{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:30:31Z","timestamp":1774294231416,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the effect of Fufang Huangqi Decoction on the gut microbiota in patients with class I or II myasthenia gravis (MG) and to explore the correlation between gut microbiota and MG (registration number, ChiCTR2100048367; registration website, <jats:ext-link>http:\/\/www.chictr.org.cn\/listbycreater.aspx<\/jats:ext-link>; NCBI: SRP338707).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, microbial community composition and diversity analyses were carried out on fecal specimens from MG patients who did not take Fufang Huangqi Decoction (control group, <jats:italic>n<\/jats:italic> = 8) and those who took Fufang Huangqi Decoction and achieved remarkable alleviation of symptoms (medication group, <jats:italic>n<\/jats:italic> = 8). The abundance, diversity within and between habitats, taxonomic differences and corresponding discrimination markers of gut microbiota in the control group and medicated group were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with the control group, the medicated group showed a significantly decreased abundance of Bacteroidetes (<jats:italic>P<\/jats:italic> &amp;lt; 0.05) and significantly increased abundance of Actinobacteria at the phylum level, a significantly decreased abundance of Bacteroidaceae (<jats:italic>P<\/jats:italic> &amp;lt; 0.05) and significantly increased abundance of Bifidobacteriaceae at the family level and a significantly decreased abundance of <jats:italic>Blautia<\/jats:italic> and <jats:italic>Bacteroides<\/jats:italic> (<jats:italic>P<\/jats:italic> &amp;lt; 0.05) and significantly increased abundance of <jats:italic>Bifidobacterium, Lactobacillus<\/jats:italic> and <jats:italic>Roseburia<\/jats:italic> at the genus level. Compared to the control group, the medicated group had decreased abundance, diversity, and genetic diversity of the communities and increased coverage, but the differences were not significant (<jats:italic>P<\/jats:italic> &amp;gt; 0.05); the markers that differed significantly between communities at the genus level and influenced the differences between groups were <jats:italic>Blautia, Bacteroides, Bifidobacterium<\/jats:italic> and <jats:italic>Lactobacillus<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MG patients have obvious gut microbiota-associated metabolic disorders. Fufang Huangqi Decoction regulates the gut microbiota in patients with class I or II MG by reducing the abundance of <jats:italic>Blautia<\/jats:italic> and <jats:italic>Bacteroides<\/jats:italic> and increasing the abundance of <jats:italic>Bifidobacterium<\/jats:italic> and <jats:italic>Lactobacillus<\/jats:italic>. The correlation between gut microbiota and MG may be related to cell-mediated immunity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.785040","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T04:59:29Z","timestamp":1647579569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Fufang Huangqi Decoction on the Gut Microbiota in Patients With Class I or II Myasthenia Gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanghong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caifeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rencai","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve."},{"key":"B3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the normal gut microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jvim.14875","article-title":"The gastrointestinal microbiome: a review","volume":"32","author":"Barko","year":"2018","journal-title":"J Vet Intern Med."},{"key":"B7","first-page":"206","article-title":"The gut microbiome","volume":"46","author":"Sidhu","year":"2017","journal-title":"Aust Fam Physician."},{"key":"B8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ilar\/ilv030","article-title":"The intestinal microbiota in inflammatory bowel disease","volume":"56","author":"Becker","year":"2015","journal-title":"ILAR J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/jcmm.14195","article-title":"The role of intestinal microbiota in cardiovascular disease","volume":"23","author":"Jin","year":"2019","journal-title":"J Cell Mol Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"300060520936806","DOI":"10.1177\/0300060520936806","article-title":"Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes","volume":"48","author":"Wang","year":"2020","journal-title":"J Int Med Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3748\/wjg.v22.i1.361","article-title":"Gut microbiota in autism and mood disorders","volume":"22","author":"Mangiola","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1901441","DOI":"10.1002\/advs.201901441","article-title":"Perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome","volume":"6","author":"Zheng","year":"2019","journal-title":"Adv Sci (Weinh)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14384","DOI":"10.1038\/s41598-018-32700-y","article-title":"Fecal microbiota profile in a group of myasthenia gravis patients","volume":"8","author":"Moris","year":"2018","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.13192\/j.issn.1000-1719.2018.07.005","article-title":"Effect evaluation of Fufang Huangqi granules on spleen and kidney deficiency type and type myasthenia gravis[J]Liaoning","volume":"45","author":"Qiao","year":"2018","journal-title":"J Traditi Chin Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology."},{"key":"B18","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mt Sinai J Med."},{"key":"B19","first-page":"87","article-title":"A clinical absolute and relative score system for myasthenia gravis","volume":"30","author":"Wang","year":"1997","journal-title":"Chin J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40779-017-0122-9","article-title":"Interaction between the gut microbiome and mucosal immune system","volume":"4","author":"Shi","year":"2017","journal-title":"Mil Med Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"736036","DOI":"10.3389\/fimmu.2021.736036","article-title":"Proton pump inhibitors increase the risk of autoimmune diseases: a nationwide cohort study","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12765","article-title":"Intestinal dysbiosis and probiotic applications in autoimmune diseases","volume":"152","author":"de Oliveira","year":"2017","journal-title":"Immunology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4835189","DOI":"10.1155\/2017\/4835189","article-title":"Intestinal dysbiosis and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis","volume":"2017","author":"Horta-Baas","year":"2017","journal-title":"J Immunol Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.3390\/ijms20194871","article-title":"Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus","volume":"20","author":"Kim","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3748\/wjg.v24.i37.4217","article-title":"Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome","volume":"24","author":"Camara-Lemarroy","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/19490976.2017.1290757","article-title":"Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease","volume":"8","author":"Weingarden","year":"2017","journal-title":"Gut Microbes."},{"key":"B27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nri2515","article-title":"The gut microbiota shapes intestinal immune responses during health and disease","volume":"9","author":"Round","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/imr.12039","article-title":"CD4(+) T-cell subsets in intestinal inflammation","volume":"252","author":"Shale","year":"2013","journal-title":"Immunol Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflammation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"593431","DOI":"10.3389\/fneur.2020.593431","article-title":"Immunoregulatory cells in myasthenia gravis","volume":"11","author":"Wu","year":"2020","journal-title":"Front Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3389\/fmicb.2018.02627","article-title":"Altered gut microbiota in myasthenia gravis","volume":"9","author":"Qiu","year":"2018","journal-title":"Front Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"22269","DOI":"10.18632\/oncotarget.25170","article-title":"Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewisrats","volume":"9","author":"Consonni","year":"2018","journal-title":"Oncotarget."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.3389\/fimmu.2019.02949","article-title":"Therapeutic effect of bifidobacterium administration on experimental autoimmune myasthenia gravis in lewis rats","volume":"10","author":"Rinaldi","year":"2019","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"564579","DOI":"10.3389\/fmicb.2020.564579","article-title":"Differential gut microbiota and fecal metabolites related with the clinical subtypes of myasthenia gravis","volume":"11","author":"Tan","year":"2020","journal-title":"Front Microbiol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.785040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T04:59:36Z","timestamp":1647579576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.785040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":34,"alternative-id":["10.3389\/fneur.2022.785040"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.785040","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"article-number":"785040"}}